Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regulates cortisol levels, and its excess is linked to insulin resistance and metabolic syndrome.
• Inhibition of 11β-HSD1 is a therapeutic target for type 2 diabetes.
• Numerous potent and selective small molecule inhibitors for 11β-HSD1 have been discovered.

Purpose of the Study:

• To review recent advancements in the discovery and development of small molecule inhibitors of 11β-HSD1.
• To highlight medicinal chemistry, structure-activity relationships (SAR), and in vivo effects of these inhibitors.
• To analyze structural characteristics using co-crystal structures of 11β-HSD1 inhibitors.

Main Methods:

• Literature review of recent progress in small molecule inhibitor development for 11β-HSD1.
• Analysis of medicinal chemistry, SAR, and in vivo pharmacodynamic effects.
• Examination of co-crystal structures to understand inhibitor binding.

Main Results:

• Several chemical classes of potent and selective 11β-HSD1 inhibitors have been identified.
• Medicinal chemistry efforts have yielded promising compounds for treating diabetes models.
• Co-crystal structures provide insights into the mechanism of inhibition.

Conclusions:

• Small molecule inhibitors of 11β-HSD1 represent a viable therapeutic strategy for type 2 diabetes.
• Continued research in medicinal chemistry and structural biology will drive further development.
• These inhibitors show potential for managing metabolic syndrome and insulin resistance.